Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.86 USD

103.86
156,105

+0.90 (0.87%)

Updated Aug 8, 2025 10:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Syneos Health (SYNH) to Launch Serplulimab With New Pact

by Zacks Equity Research

Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.

Zacks Equity Research

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit

by Zacks Equity Research

A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.

Zacks Equity Research

QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen

by Zacks Equity Research

QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.

Zacks Equity Research

Illumina (ILMN), Nashville Biosciences Partner With Amgen

by Zacks Equity Research

Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.

Zacks Equity Research

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

by Zacks Equity Research

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Zacks Equity Research

Abbott's (ABT) New Launch to Boost Blood Donation Experience

by Zacks Equity Research

Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.

Zacks Equity Research

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.

Zacks Equity Research

LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays

by Zacks Equity Research

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Sheraz Mian headshot

Top Research Reports for Caterpillar, Equinor & GSK

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Caterpillar Inc. (CAT), Equinor ASA (EQNR) and GSK plc (GSK).

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.

Zacks Equity Research

Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.

Zacks Equity Research

Alcon (ALC) Gains From Innovation, Faces FX Challenges

by Zacks Equity Research

Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Zacks Equity Research

Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business

by Zacks Equity Research

Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.

Zacks Equity Research

Walgreens Boots (WBA) Q1 Earnings Top, Revenues View Up

by Zacks Equity Research

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

Zacks Equity Research

Here's Why You Should Hold Cigna (CI) Stock in Your Portfolio

by Zacks Equity Research

Cigna (CI) remains well-poised for growth on the back of the solid Evernorth and Cigna Healthcare businesses, an expanding customer base and robust cash-generating abilities.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

Zacks Equity Research

Masimo's (MASI) SpHb During Elective CS Favored by New Study

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.

Zacks Equity Research

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

Zacks Equity Research

PETQ vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

PETQ vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Walgreens' (WBA) strategic executions on both the United States and the international front are likely to have contributed to the Q1 2023 top line.